Core Viewpoint - The company has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan [1] Group 1: Partnership Details - The agreement grants Dongshenghua Pharmaceutical exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sale of BRIMOCHOL™ PF [1] Group 2: Regulatory Milestones - In June 2025, Tenpoint Therapeutics, Ltd., the developer of BRIMOCHOL™ PF, announced that the FDA has accepted the new drug application for the product [1] - The FDA has set a review deadline for BRIMOCHOL™ PF under the Prescription Drug User Fee Act (PDUFA) for January 28, 2026 [1]

Core Viewpoint - The company Zhaoke Ophthalmology-B (06622.HK) has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan [1] Group 1: Partnership Details - Zhaoke grants Dongshenghua exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sale of BRIMOCHOL™ PF [1] Group 2: Regulatory Milestones - In June 2025, Tenpoint Therapeutics, Ltd., the developer of BRIMOCHOL™ PF, announced that the FDA has accepted the new drug application for the product [1] - The FDA has set a Prescription Drug User Fee Act (PDUFA) review deadline for BRIMOCHOL™ PF on January 28, 2026 [1]

Core Viewpoint - The company, Zhaoke Ophthalmology-B (06622.HK), has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan [1] Group 1: Partnership Details - Zhaoke grants Dongshenghua exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sale of BRIMOCHOL™ PF [1] - Dongshenghua specializes in chronic diseases and precision medicine, providing safe and accessible healthcare solutions [1] Group 2: Regulatory Updates - In June 2025, Tenpoint Therapeutics, the developer of BRIMOCHOL™ PF, announced that the U.S. FDA has accepted the new drug application for the product [1] - The FDA has set a review deadline for the Prescription Drug User Fee Act (PDUFA) for BRIMOCHOL™ PF on January 28, 2026 [1]

根据协议条款，兆科授予东生华制药以独家分销商身份于台湾地区注册、进口、推广、分销、营销及销 售BRIMOCHOL™ PF的权利。 于2025年6月，兆科的伙伴兼BRIMOCHOL™ PF的开发商Tenpoint Therapeutics, Ltd.宣布，美国FDA已受 理该药品的新药上市申请("新药申请")。FDA已就BRIMOCHOL™ PF制定处方药使用者付费法案 (Prescription Drug User Fee Act)("PDUFA")，审核截止日期为2026年1月28日。 格隆汇12月8日丨兆科眼科-B(06622.HK)发布公告，公司与以台湾为基地的东生华制药股份有限公司订 立策略性伙伴关系，于台湾地区共同推进BRIMOCHOL™ PF的临床导论及未来商业化。东生华制药精 于慢性病及精准医疗，提供安全而易于获取的照护解决方案。 来源：格隆汇APP ...

Group 1 - The company Zhaoke Ophthalmology-B (06622) has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan [1] - Dongshenghua Pharmaceutical specializes in chronic diseases and precision medicine, providing safe and accessible healthcare solutions [1] - Under the agreement, Zhaoke grants Dongshenghua exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sales of BRIMOCHOL™ PF [1] Group 2 - By June 2025, Tenpoint Therapeutics, Ltd., a partner of Zhaoke and developer of BRIMOCHOL™ PF, announced that the FDA has accepted the new drug application for the product [1] - The FDA has set a review deadline for BRIMOCHOL™ PF under the Prescription Drug User Fee Act (PDUFA) for January 28, 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Zhaoke Ophthalmology Limited （於英屬處女群島註冊成立並於開曼群島存續的有限公司） 兆科眼科有限公司 （股份代號：6622） 自 願 性 公 告－ 就於台灣地區 商業化BRIMOCHOL™ PF與 東生華製藥訂立策略性夥伴關係 本 公 告 乃 由 兆 科 眼 科 有 限 公 司（「本公司」）董 事 會（「董事會」）自 願 作 出。 本 公 司 董 事 會 欣 然 宣 佈，本 公 司 與 以 台 灣 為 基 地 的 東 生 華 製 藥 股 份 有 限 公 司 訂 立 策 略 性 夥 伴 關 係，於 台 灣 地 區 共 同 推 進BRIMOCHOL™ PF的臨床導論及未 來 商 業 化。東 生 華 製 藥 精 於 慢 性 病 及 精 準 醫 療，提 供 安 全 而 易 於 獲 取 的 照 護 解 決 方 案。 根 據 協 議 ...

Group 1: Airline Sector - Major domestic airlines in China, including China Eastern Airlines, Air China, and China Southern Airlines, reported revenue growth and profitability for the third quarter of 2025, supported by summer travel and foreign exchange gains [1] - China Eastern Airlines (00670) rose by 4.65%, Air China (00753) increased by 6.31%, and China Southern Airlines (01055) gained 4.85% in early trading [1] Group 2: Infrastructure and Construction - China Liansu (02128) saw a rise of over 5.5% following the announcement of plans to construct and renovate over 700,000 kilometers of underground pipelines, with an investment demand exceeding 5 trillion yuan during the 14th Five-Year Plan [1] Group 3: Consumer Goods and Retail - Pop Mart (09992) surged over 6.64% as a report indicated a 245-250% increase in overall revenue for the third quarter of 2025, with domestic revenue growing by 185-190% and overseas revenue by 365-370% [1] - Wei Long (09985) increased by over 6.8% due to a Goldman Sachs report highlighting a favorable risk-reward profile after a 30% price correction since April [4] Group 4: Renewable Energy and Technology - Aidi New Energy (02623) rose by over 13.67% after announcing a change in control, with PIH becoming the new controlling shareholder [2] - Global energy storage battery shipments reached 428 GWh in the first nine months of 2025, marking a significant year-on-year increase of 90.7%, benefiting companies like Ruipu Lanjun (00666), which saw a nearly 8% rise [2] Group 5: Pharmaceuticals - Gilead Sciences-B (01672) increased by over 6.98% after being included in the MSCI Global Small Cap Index, effective November 24 [2] - Zhaoke Ophthalmology-B (06622) rose over 10.3% following a distribution agreement with a leading Indonesian pharmaceutical company for its innovative eye treatment [3] Group 6: Metals and Mining - Century Aluminum (CENX.US) reported a revenue of $632.2 million for Q3 2025, a 17.3% year-on-year increase, primarily driven by price increases in the Midwest [5] - Rare earth stocks saw significant gains, with MP Materials rising over 12.8% [5] Group 7: Technology and E-commerce - Airbnb (ABNB.US) reported Q3 2025 revenue of approximately $4.1 billion, a 10% year-on-year increase, with net profit around $1.4 billion [7] - Akamai (AKAM.US) saw a 14.71% increase after reporting a non-GAAP EPS of $1.86, exceeding market expectations [7]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) experienced a nearly 10% increase in stock price, reaching HKD 3.7 with a trading volume of HKD 6.55 million following the announcement of a distribution and supply agreement with PT Ferron Par Pharmaceuticals for its innovative drug BRIMOCHOL™ PF in Indonesia [1] Company Summary - Zhaoke Ophthalmology has signed a distribution and supply agreement with PT Ferron Par Pharmaceuticals, a leading pharmaceutical company in Indonesia [1] - The agreement grants PT Ferron exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL™ PF in Indonesia [1] - Zhaoke Ophthalmology will receive an upfront payment and may earn additional milestone payments based on certain achievements [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 7% following the announcement of a distribution and supply agreement with PT Ferron Par Pharmaceuticals for its innovative drug BRIMOCHOL™ PF, aimed at treating presbyopia in the Indonesian market [1] Company Developments - Zhaoke Ophthalmology has signed a distribution and supply agreement with PT Ferron, a leading pharmaceutical company in Indonesia, granting exclusive rights for the import, promotion, distribution, marketing, and sale of BRIMOCHOL™ PF in Indonesia [1] - The agreement includes an upfront payment to Zhaoke Ophthalmology, along with potential milestone payments based on certain achievements [1] Product Information - BRIMOCHOL™ PF is an innovative drug developed for the treatment of presbyopia, with its rights licensed from Tenpoint Therapeutics, Ltd. [1] - Tenpoint Therapeutics has submitted a new drug application to the U.S. Food and Drug Administration (FDA), with the Prescription Drug User Fee Act (PDUFA) date set for January 28, 2026 [1]

Group 1 - The company has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the commercialization of BRIMOCHOL™ PF in Indonesia, granting PT Ferron exclusive rights for import, promotion, distribution, marketing, and sales of the product [1] - The company will receive an upfront payment and may earn additional milestone payments based on specific achievements [1] - The developer of BRIMOCHOL™ PF, Tenpoint Therapeutics, announced that the FDA has accepted the new drug application for the product, with a review deadline set for January 28, 2026 [1] Group 2 - BRIMOCHOL™ PF is a preservative-free, experimental eye drop intended to correct near vision loss due to aging, and is part of a multi-center, randomized, double-blind study involving 629 participants across 47 trial centers in the U.S. [2] - The study compares the safety and efficacy of BRIMOCHOL™ PF with other treatments for presbyopia [2] Group 3 - PT Ferron Par Pharmaceuticals, a member of the Dexa Group, has been operating since 2001 and is one of the top 15 largest pharmaceutical companies in Indonesia according to IQVIA data [3] - The company has received recognition from regulatory agencies in the UK and Portugal, enhancing its market influence and operational capabilities through a diverse product portfolio and strong strategic partnerships [3]